Jingwu Zhang Zang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jingwu zhang zang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jingwu Zhang Zang Today - Breaking & Trending Today

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization. ....

United States , Hong Kong , San Diego , Emilie Wu , Zheru Zhang , Jingwu Zhang Zang , Andrew Zhu , Gigi Feng , Jingwu Zang , Jielun Zhu , Weimin Tang , Yifei Zhu , Wei Fu , Richard Li , John Long , Company Nasdaq , Fortune Eight Jogging , Piacente Group Inc , Exchange Commission , Hony Capital , Key Shareholders , Bridge Capital , Fortune Eight Jogging Limited , Acting Chief Executive Officer , President Andrew Zhu , President Zheru Zhang ,

I-MAB (IMAB) Gets a Buy Rating from Needham

I-MAB (IMAB) Gets a Buy Rating from Needham
markets.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from markets.co Daily Mail and Mail on Sunday newspapers.

Jingwu Zhang Zang , Gil Blum , Rocket Pharmaceuticals , Research Report , Crispr Therapeutics , Taysha Gene , Strong Buy ,

I-MAB (IMAB) Q2 2021 Earnings Call Transcript

I-MAB (IMAB) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , San Diego , Jennifer Kim Cantor Fitzgerald , Joan Huaqiong Shen , Jingwu Zhang Zang , Jen Kim , Jingwu Zang , Jielun Zhu , Louise Chen , Kelly Shi Jefferies , Joan Shen , Zhang Wenhong , Kelly Shi , Henan Charity , National Drug Reimbursement List , Women Leadership Councils , Enterprises Of Technology Power , Chief Financial , Business Update , Financial Results Conference , Chief Executive , Greater China , Professor Zhang Wenhong , Huashan Hospital , Institutional Investor ,

I-MAB (IMAB) Gets a Buy Rating from Needham

I-MAB (IMAB) Gets a Buy Rating from Needham
In a report released today, Chad Messer from Needham assigned a Buy rating to I-MAB (IMAB – Research Report), with a price target of $75.00. The company’s shares closed last Monday at $64.01, close to its 52-week high of $65.94.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 8.0% and a 46.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.
Currently, the analyst consensus on I-MAB is a Strong Buy with an average price target of $75.20.
Based on I-MAB’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.54 billion and net profit of $1.04 billion. In comparison, last year the company earned revenue of $15 million and had a GAAP net loss of $246 million. ....

Jingwu Zhang Zang , Aeglea Biotherapeutics , Mereo Biopharma Group Plc , Phasebio Pharmaceuticals , Chad Messer , Research Report , Strong Buy , சாட் மெஸர் , ஆராய்ச்சி அறிக்கை , வலுவான வாங்க ,